Methotrexate (MTX) is significantly more effective than and has a considerable advantage
over placebo in patients with severe and persistent rheumatoid arthritis (RA). The drug is …

Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that
affects children and adults. Until recently, the only Food and Drug Administration–approved …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with
heterogeneous clinical manifestations. To date, no therapeutic agents have been licensed …

Background Guselkumab is an interleukin (IL)‐23 inhibitor with demonstrated efficacy in
patients with psoriasis. Objectives Evaluate the impact of early disease intervention on …

Dermatologists may choose from various conventional and biological systemic agents to
treat patients with moderate‐to‐severe psoriasis. We set out to analyse systematically the …

Background Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in
patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may …

MTX is an immunosuppressant drug that occupies a key place in the management of many
autoimmune and inflammatory skin diseases. Although MTX has been widely prescribed in …

Psoriasis is a highly prevalent disease with a major impact on quality of life; therefore,
appropriate patient management is mandatory. Given that many issues in psoriasis are …

As the first biologics for psoriasis in Japan, infliximab and adalimumab, anti‐tumor necrosis
factor‐α antibodies, became available in the field of dermatology in 2010, followed by …